PBM -
Psyence Biomedical Ltd. Common Shares
| Day |
1m |
10m |
60m |
PreMarket |
Market |
AfterHours |
Gap |
| 1.52 -0.03 (-2.18%) |
0.0 (0.0%) |
0.01 (0.46%) |
-0.05 (-3.42%) |
0.06 (3.95%) |
-0.06 (-4.08%) |
-0.07 (-4.11%) |
-0.12 (-7.06%) |
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.
Earnings & Ratios
- Basic EPS:
- Diluted EPS:
- Basic P/E:
- Diluted P/E:
- RSI(14) 1m:
- 43.74
- VWAP:
- 1.49
- RVol:
Events
| Period |
Kind |
Movement |
Occurred At |
Related News
Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science
Dec 09, 2025 12:00
Psyence BioMed Strengthens Strategic Partnership with PsyLabs Through USD $3,500,000 Follow-On Investment
Nov 03, 2025 12:00
US Stocks To Open Lower As Traders Brace For 'Triple Witching' Hour: Analyst Says End Of The Year Recovery 'Would Not Surprise Anyone'
Dec 20, 2024 10:37
Psyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group's Stake in PsyLabs
Oct 31, 2024 11:30
Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs
Sep 19, 2024 11:30
Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant
Sep 06, 2024 11:30
Psyence Biomed Announces Registration Statement on Form F-1 for Up to $25 Million Equity Line of Credit with White Lion Capital, LLC, Declared Effective by SEC
Aug 30, 2024 11:00
Psyence Biomed to Participate in the A.G.P. Virtual Healthcare Company Showcase
May 17, 2024 11:00
Psyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
Apr 16, 2024 15:01
Psyence Biomed Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
Apr 08, 2024 12:00